The Malaysian health ministry has approved the registration of Xenpozyme (Olipudase alfa 20mg), an enzyme replacement therapy product for treating acid sphingomyelinase deficiency (ASMD), a rare genetic disorder. This approval comes after priority evaluation by the National Pharmaceutical Regulatory Authority to provide immediate access for patients.
Follow us on:
Read More News #latestmalaysia
Xenpozyme Treatment ASMD
Enzyme replacement therapy is the first specific treatment for ASMD and can help reduce fat accumulation in organ cells and alleviate symptoms of the disease. ASMD patients lack an enzyme necessary for breaking down sphingomyelin complex fat, leading to fat accumulation in various organs, ultimately causing premature death from respiratory.
More Photos
